Multiple endocrine neoplasia type 2 screening: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
|||
Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 2}} | {{Multiple endocrine neoplasia type 2}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by ''RET'' gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2. | According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by ''RET'' gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2. | ||
==Screening== | ==Screening== | ||
* The [[DNA]]-based testing of the c-''RET'' gene is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-''RET'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. This test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]]. | * The [[DNA]]-based testing of the c-''RET'' gene is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-''RET'' germline [[mutation]]s, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant [[gene]] carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic [[thyroidectomy]] before the clinical expression of the [[tumor]]. This test is also of importance to detect and thus, to reduce the risk of an unsuspected [[pheochromocytoma]]. | ||
Line 30: | Line 32: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Oncology | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 14:11, 21 July 2016
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2. It can be easily performed on a blood sample at any age. It offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor. This test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.
- Screening for multiple endocrine neoplasia type 2 include the following tests.
References
[[Category:Oncology |